Neurodegeneration in an adolescent with Sjogren-Larsson syndrome: a decade-long follow-up case report

被引:4
作者
Cho, Kye Hee [1 ]
Shim, Sung Han [2 ]
Jung, Youngsoo [1 ]
Sung, Se Ra [3 ]
Kim, MinYoung [1 ]
机构
[1] CHA Univ, Dept Rehabil Med, CHA Bundang Med Ctr, 59 Yatap Ro, Seongnam 13496, Gyeonggi Do, South Korea
[2] CHA Univ, Dept Biomed Sci, Coll Life Sci, 120 Haeryong Ro, Pochun 11160, Gyeonggi Do, South Korea
[3] CHA Univ, Genet Lab, Fertil Ctr, CHA Gangnam Med Ctr, Seoul 06135, South Korea
来源
BMC MEDICAL GENETICS | 2018年 / 19卷
基金
新加坡国家研究基金会;
关键词
Neurodegeneration; Sjogren-Larsson syndrome; Dystonia; Neurologic deterioration; ALDEHYDE DEHYDROGENASE GENE; MUTATIONS; UPDATE;
D O I
10.1186/s12881-018-0663-0
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Sjogren-Larsson syndrome is a hereditary neurocutaneous syndrome that is non-progressive in nature. Although neuroregression has been reported in seizure-prone preschool children requiring anti-epileptic treatment, teenage-onset dystonia precipitating neurodegeneration without any immediate causal events has yet to be reported. Case presentation: We describe a young woman with spastic diplegia and intellectual disability who began to show progressive neurological deterioration from 12 years of age, with the onset of dystonia and tremor. She was initially diagnosed with spastic cerebral palsy and periventricular leukomalacia based on brain magnetic resonance imaging. Follow-up brain imaging from 13 years of age did not reveal apparent changes, though abnormal electroencephalographic findings occurred in parallel with her decline in motor function. By 19 years of age, she had developed dysphagia and became completely dependent on others for most activities of daily living. Ultimately, whole-exome sequencing revealed a heterozygous compound mutation in the ALDH3A2 gene that corresponds to Sjogren-Larsson syndrome: an exon 9 deletion (1291-1292delAA) from the mother and an exon 5 splicing mutation (798 + 1delG) from the father. Neuroregression has been reported in preschool children after seizures requiring treatment, though our patient did not experience any immediate causal events. This report summarizes the clinical, radiologic, and electrophysiological findings observed over a decade concurrent with neurological deterioration after the onset of dystonia and tremor at the age of developmental ceiling in Sjogren-Larsson syndrome. Conclusions: In addition to the influence of additive variants or other environmental factors, accumulation of metabolites due to defective fatty aldehyde dehydrogenase is a potential pathomechanism of neurodegeneration in this patient. Neurological deterioration may be a presentation that is unnoticed in Sjogren-Larsson syndrome due to the rarity of the disease. This report highlights a unique clinical feature of Sjogren-Larsson syndrome with progressive neurodegeneration associated with dystonia and tremor.
引用
收藏
页数:5
相关论文
共 16 条
  • [1] Willemsen M.A., Ijlst L., Steijlen P.M., Rotteveel J.J., de Jong J.G., van Domburg P.H., Mayatepek E., Gabreels F.J., Wanders R.J., Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome, Brain, 124, 7, pp. 1426-1437, (2001)
  • [2] Fuijkschot J., Theelen T., Seyger M.M., van der Graaf M., de Groot I.J., Wevers R.A., Wanders R.J., Waterham H.R., Willemsen M.A., Sjogren-Larsson syndrome in clinical practice, J Inherit Metab Dis, 35, 6, pp. 955-962, (2012)
  • [3] Rosenbaum P., Paneth N., Leviton A., Goldstein M., Bax M., Damiano D., Dan B., Jacobsson B., A report: the definition and classification of cerebral palsy April 2006, Dev Med Child Neurol Suppl, 109, pp. 8-14, (2007)
  • [4] Rizzo W.B., Carney G., Lin Z., The molecular basis of Sjogren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene, Am J Hum Genet, 65, 6, pp. 1547-1560, (1999)
  • [5] Cho K.H., Shim S.H., Kim M., Clinical, biochemical, and genetic aspects of Sjogren-Larsson syndrome, Clin Genet, 93, 4, pp. 721-730, (2018)
  • [6] Rizzo W.B., Sjogren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency, Mol Genet Metab, 90, 1, pp. 1-9, (2007)
  • [7] Demozay D., Mas J.C., Rocchi S., Van Obberghen E., FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes, Diabetes, 57, 5, pp. 1216-1226, (2008)
  • [8] Zarkovic K., 4-Hydroxynonenal and neurodegenerative diseases, Mol Asp Med, 24, 4-5, pp. 293-303, (2003)
  • [9] Verhoog J., Fuijkschot J., Willemsen M., Ketelaar M., Rotteveel J., Gorter J.W., Sjogren-Larsson syndrome: motor performance and everyday functioning in 17 patients, Dev Med Child Neurol, 50, 1, pp. 38-43, (2008)
  • [10] Kaye E.M., Update on genetic disorders affecting white matter, Pediatr Neurol, 24, 1, pp. 11-24, (2001)